These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14769009)

  • 1. Italian drug policy: ethical aims of essential assistance levels.
    Bernardi A; Pegoraro R
    Health Care Anal; 2003 Dec; 11(4):279-86. PubMed ID: 14769009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Statins and hypertension].
    Madsen S
    Tidsskr Nor Laegeforen; 2004 Sep; 124(17):2277; author reply 2277. PubMed ID: 15356707
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lean years for patients].
    Klose G; Anlauf M
    MMW Fortschr Med; 2004 Dec; 146(51-52):16. PubMed ID: 15675237
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization.
    Meissner B; Dickson M; Shinogle J; Reeder CE; Belazi D; Senevirante V
    J Manag Care Pharm; 2006 May; 12(4):331-40. PubMed ID: 16792439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problematic notions in Dutch health care package decisions.
    Hoedemaekers R; Oortwijn W
    Health Care Anal; 2003 Dec; 11(4):287-94. PubMed ID: 14769010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What price atorvastatin?
    Drug Ther Bull; 2012 Jul; 50(7):73. PubMed ID: 22764068
    [No Abstract]   [Full Text] [Related]  

  • 7. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Justice and solidarity in priority setting in health care.
    Hoedemaekers R; Dekkers W
    Health Care Anal; 2003 Dec; 11(4):325-43. PubMed ID: 14769014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of China's national essential medicines policy.
    Guan X; Liang H; Xue Y; Shi L
    J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from Lipitor and the broken blockbuster drug model.
    The Lancet
    Lancet; 2011 Dec; 378(9808):1976. PubMed ID: 22153189
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to essential drugs, human rights and global justice.
    Shalev C
    Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
    [No Abstract]   [Full Text] [Related]  

  • 16. National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities.
    Yoongthong W; Hu S; Whitty JA; Wibulpolprasert S; Sukantho K; Thienthawee W; Han H; Scuffham PA
    Value Health; 2012; 15(1 Suppl):S126-31. PubMed ID: 22265059
    [No Abstract]   [Full Text] [Related]  

  • 17. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
    Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
    Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid profile changes associated with changing available formulary statins: removing higher potency agents.
    Longyhore DS; Stockton CM; Thomas MR
    Am J Manag Care; 2009 Jul; 15(7):409-14. PubMed ID: 19589008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
    Gizurarson S; Björnsdóttir LR; Einarsdóttir R; Halldórsson M; Andersen K
    Scand J Public Health; 2012 Nov; 40(7):663-7. PubMed ID: 23027893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.